Personensuche
Personensuche
Es wurde 1 Person gefunden.
Funktionen
-
Assistenzarzt/-ärztin, Klinik für Dermatologie
Aktuelle Veranstaltungen
-
2024 WS
Vergangene Veranstaltungen (max. 10)
-
2024 SS
-
2023 WS
-
2023 SS
-
2022 WS
-
2022 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
A Systematic Comparison of Task Adaptation Techniques for Digital HistopathologyIn: Bioengineering Jg. 11 (2024) Nr. 1, 19Online Volltext: dx.doi.org/ (Open Access)
-
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaIn: European Journal of Cancer (EJC) Jg. 202 (2024) 113976Online Volltext: dx.doi.org/ (Open Access)
-
Arzneimittelexantheme unter Immun- und zielgerichteter onkologischer TherapieIn: Die Dermatologie Jg. 75 (2024) Nr. 6, S. 440 - 450Online Volltext: dx.doi.org/
-
Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 200 (2024) 113536Online Volltext: dx.doi.org/ (Open Access)
-
BioKGrapher : Initial evaluation of automated knowledge graph construction from biomedical literatureIn: Computational and Structural Biotechnology Journal Jg. 24 (2024) S. 639 - 660Online Volltext: dx.doi.org/ (Open Access)
-
Case report: : Durable complete response of a mucosal melanoma of the rectum after neoadjuvant immunotherapy with ipilimumab plus nivolumabIn: Frontiers in Immunology Jg. 15 (2024) 1369190Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanomaIn: Frontiers in Immunology Jg. 15 (2024) 1383125Online Volltext: dx.doi.org/ (Open Access)
-
Early versus late response to PD-1-based immunotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 210 (2024) 114295Online Volltext: dx.doi.org/ (Open Access)
-
Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas : A multicentric study in 100 patientsIn: Journal of the European Academy of Dermatology and Venereology Jg. 38 (2024) Nr. 5, S. 954 - 966Online Volltext: dx.doi.org/ (Open Access)
-
Mitigating cognitive bias with clinical decision support systems : An experimental studyIn: Journal of Decision Systems Jg. 33 (2024) Nr. 3, S. 439 - 458Online Volltext: dx.doi.org/
-
Pegylated interferon-α2a in cutaneous T-cell lymphoma : a multicenter retrospective data analysis with 70 patientsIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A) : The doctors’ perspectiveIn: Journal of Cancer Research and Clinical Oncology Jg. 150 (2024) Nr. 5, 252Online Volltext: dx.doi.org/ (Open Access)
-
Psychosocial distress and psychosocial resources in couples facing non-melanoma skin cancers and malignant melanomaIn: Journal of Psychosocial Oncology (2024) in pressOnline Volltext: dx.doi.org/
-
Requirements for a dashboard optimized for melanoma patient care through user-centered context explorationIn: Scientific Reports Jg. 14 (2024) Nr. 1, 17471Online Volltext: dx.doi.org/ (Open Access)
-
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomasIn: European Journal of Cancer (EJC) Jg. 208 (2024) 114208Online Volltext: dx.doi.org/ (Open Access)
-
Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signatureIn: Frontiers in Oncology Jg. 14 (2024) 1408614Online Volltext: dx.doi.org/ (Open Access)
-
Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type : A case series and review of the literatureIn: The Journal of Dermatology Jg. 51 (2024) Nr. 9, S. 1233 - 1239Online Volltext: dx.doi.org/ (Open Access)
-
The Mappability of Clinical Real-World Data of Patients with Melanoma to Oncological Fast Healthcare Interoperability Resources (FHIR) Profiles : A Single-Center Interoperability StudyIn: Informatics Jg. 11 (2024) Nr. 3, 42Online Volltext: dx.doi.org/ (Open Access)
-
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrationsIn: European Journal of Cancer (EJC) Jg. 202 (2024) 113984Online Volltext: dx.doi.org/ (Open Access)
-
Tinea capitis due to Trichophyton soudanense and Microsporum audouinii : A surprising findingIn: JEADV Clinical Practice Jg. 3 (2024) Nr. 3, Skin Diversity, S. 887 - 890Online Volltext: dx.doi.org/ (Open Access)
-
Use of Real-World FHIR Data Combined with Context-Sensitive Decision Modeling to Guide Sentinel Biopsy in MelanomaIn: Journal of Clinical Medicine (JCM) Jg. 13 (2024) Nr. 11, 3353Online Volltext: dx.doi.org/ (Open Access)
-
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O) : disease-free survival results from a randomised, open-label, phase 2 trialIn: Lancet Jg. 402 (2023) Nr. 10404, S. 798 - 808Online Volltext: dx.doi.org/
-
Adjuvant treatment and outcome of stage III melanoma patients : Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) studyIn: European Journal of Cancer (EJC) Jg. 191 (2023) 112957Online Volltext: dx.doi.org/
-
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer Jg. 4 (2023) Nr. 9, S. 1395Online Volltext: dx.doi.org/ (Open Access)
-
BRAF inhibitor cessation prior to disease progression in metastatic melanoma : Long-term outcomesIn: European Journal of Cancer (EJC) Jg. 179 (2023) S. 87 - 97Online Volltext: dx.doi.org/
-
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 4,Online Volltext: dx.doi.org/ (Open Access)
-
COMBI-r : A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant MelanomaIn: Cancers Jg. 15 (2023) Nr. 18, 4436Online Volltext: dx.doi.org/ (Open Access)
-
Characterisation and outcome of RAC1 mutated melanomaIn: European Journal of Cancer (EJC) Jg. 183 (2023) S. 1 - 10Online Volltext: dx.doi.org/
-
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma ADOREG/TRIM : Analysis of the DeCOG prospective multicenter cohort studyIn: EBioMedicine Jg. 96 (2023) 104774Online Volltext: dx.doi.org/ (Open Access)
-
Deep learning in computational dermatopathology of melanoma : A technical systematic literature reviewIn: Computers in Biology and Medicine Jg. 163 (2023) 107083Online Volltext: dx.doi.org/ (Open Access)
-
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma : The ImmunoCobiVem phase 2 randomised trialIn: European Journal of Cancer (EJC) Jg. 190 (2023) 112941Online Volltext: dx.doi.org/
-
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 181 (2023) S. 188 - 197Online Volltext: dx.doi.org/
-
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapyIn: Journal for ImmunoTherapy of Cancer Jg. 11 (2023) Nr. 3, e006629Online Volltext: dx.doi.org/ (Open Access)
-
Fertilität, Teratogenität und Kontrazeption bei BRAF-/MEK-InhibitionIn: Die Dermatologie Jg. 74 (2023) Nr. 7, S. 496 - 500Online Volltext: dx.doi.org/
-
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma : a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREGIn: European Journal of Cancer (EJC) Jg. 188 (2023) S. 140 - 151Online Volltext: dx.doi.org/
-
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanomaIn: Nature Cancer Jg. 4 (2023) Nr. 9, S. 1292 - 1308Online Volltext: dx.doi.org/ (Open Access)
-
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaIn: European Journal of Cancer (EJC) Jg. 194 (2023) 113354Online Volltext: dx.doi.org/
-
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)In: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 13, S. 11705 - 11718Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic factors in the primary care of patients with Merkel cell carcinoma : A monocentric cohort study of 108 patients from a tertiary referral centreIn: JEADV Clinical Practice Jg. 2 (2023) Nr. 4, S. 810 - 818Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The Latest Option: Nivolumab and Relatlimab in Advanced MelanomaIn: Current Oncology Reports Jg. 25 (2023) Nr. 6, :647-657Online Volltext: dx.doi.org/ (Open Access)
-
The impact of the COVID-19 pandemic on the diagnosis of cutaneous melanomas : A retrospective cohort study from five European skin cancer reference centresIn: Journal of the European Academy of Dermatology and Venereology Jg. 37 (2023) Nr. 5, Special issue on melanoma: Immune check point and BRAF‐MEK inhibitors in melanoma, S. 922 - 931Online Volltext: dx.doi.org/ (Open Access)
-
Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary SyndromeIn: International Journal of Radiation Oncology, Biology, Physics Jg. 117 (2023) Nr. 1, S. 164 - 170Online Volltext: dx.doi.org/
-
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : Final results of a randomised, double-blind, phase 2 trialIn: Lancet Jg. 400 (2022) Nr. 10358, S. 1117 - 1129Online Volltext: dx.doi.org/
-
COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment : A prospective singlecenter study investigating seroconversion ratesIn: Frontiers in Oncology Jg. 12 (2022) 879876Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia : divergent outcomes in two men treated with PD-1 inhibitorsIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1: Anti PD-1 Therapy of Advanced Cutaneous Squamous Cell Carcinoma, S. 41 - 44Online Volltext: dx.doi.org/ (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine Jg. 12 (2022) Nr. 11, e1090Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical and pathological characteristics of familial melanoma with germline TERT promoter variantsIn: Pigment Cell and Melanoma Research Jg. 35 (2022) Nr. 6, S. 573 - 586Online Volltext: dx.doi.org/ (Open Access)
-
Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions : Non-interventional Cohort Study JONASIn: Acta Dermato-Venereologica Jg. 102 (2022) adv00695Online Volltext: dx.doi.org/ (Open Access)
-
Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient SurvivalIn: Cancers Jg. 14 (2022) Nr. 9, 2090Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic LesionsIn: Cancers Jg. 14 (2022) Nr. 17, 4066Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumorsIn: International Journal of Cancer Jg. 151 (2022) Nr. 9, S. 1542 - 1554Online Volltext: dx.doi.org/ (Open Access)
-
Genetic characterization of advanced conjunctival melanoma and response to systemic treatmentIn: European Journal of Cancer (EJC) Jg. 166 (2022) S. 60 - 72Online Volltext: dx.doi.org/
-
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREGIn: Journal for ImmunoTherapy of Cancer Jg. 10 (2022) Nr. 6, e004509Online Volltext: dx.doi.org/ (Open Access)
-
Low‐dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T‐cell lymphomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. 3, S. 279 - 285Online Volltext: dx.doi.org/ (Open Access)
-
Management of partial and non-responding cutaneous squamous cell carcinomaIn: Journal of the European Academy of Dermatology and Venereology Jg. 36 (2022) Nr. S1, S. 29 - 34Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanomaIn: Cancer Imaging Jg. 22 (2022) Nr. 1,Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Niedrig dosierte Ganzhautelektronenbestrahlung mit oraler Bexaroten-Erhaltungstherapie beim kutanen T-Zell-LymphomIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. 3, S. 279 - 286Online Volltext: dx.doi.org/ (Open Access)
-
Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapyIn: Journal of the American Academy of Dermatology: JAAD Jg. 86 (2022) Nr. 4, S. 889 - 891Online Volltext: dx.doi.org/ (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 3, S. 396 - 398Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyIn: European Journal of Cancer (EJC) Jg. 161 (2022) S. 99 - 107Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapyIn: European Heart Journal Jg. 43 (2022) Nr. 4, S. 316 - 329Online Volltext: dx.doi.org/
-
The Prognostic Relevance of PMCA4 Expression in Melanoma : Gender Specificity and Implications for Immune Checkpoint InhibitionIn: International Journal of Molecular Sciences (IJMS) Jg. 23 (2022) Nr. 6, 3324Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Validating Automatic Concept-Based Explanations for AI-Based Digital HistopathologyIn: Sensors Jg. 22 (2022) Nr. 14, 5346Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Allosteric and ATP-competitive MEK-inhibition in a novel spitzoid melanoma model with a raf-and phosphorylation-independent mutationIn: Cancers Jg. 13 (2021) Nr. 4, S. 829Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition : Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 ImmunohistochemistryIn: Frontiers in Oncology Jg. 11 (2021) 725549Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Case Report : Pseudomeningeosis and Demyelinating Metastasis-Like Lesions From Checkpoint Inhibitor Therapy in Malignant MelanomaIn: Frontiers in Oncology Jg. 11 (2021) S. 637185Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastasesIn: European Journal of Cancer (EJC) Jg. 152 (2021) S. 139 - 154Online Volltext: dx.doi.org/
-
Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer : A retrospective analysis of 47 casesIn: European Journal of Cancer (EJC) Jg. 150 (2021) S. 119 - 129Online Volltext: dx.doi.org/
-
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapyIn: eNeurologicalSci Jg. 22 (2021) 100324Online Volltext: dx.doi.org/ (Open Access)
-
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic MelanomaIn: Frontiers in Oncology Jg. 11 (2021) 741993Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg studyIn: Cancers Jg. 13 (2021) Nr. 10, S. 2312Online Volltext: dx.doi.org/ (Open Access)
-
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV⁶⁰⁰ mutant melanoma : safety and tolerability results from the phase I IMMU-TARGET trialIn: European Journal of Cancer (EJC) Jg. 158 (2021) S. 72 - 84Online Volltext: dx.doi.org/
-
Factors influencing the adjuvant therapy decision : Results of a real-world multicenter data analysis of 904 melanoma patientsIn: Cancers Jg. 13 (2021) Nr. 10, S. 2319Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapyIn: ESMO Open Jg. 6 (2021) Nr. 5, 100248Online Volltext: dx.doi.org/ (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology Jg. 11 (2021) 765608Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Kutanes Angiosarkom mit klinischem Bild eines Quincke-ÖdemsIn: Der Hautarzt Jg. 72 (2021) Nr. 9, S. 801 - 804Online Volltext: dx.doi.org/ (Open Access)
-
Leptomeningeal disease from melanoma : Poor prognosis despite new therapeutic modalitiesIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 395 - 404Online Volltext: dx.doi.org/
-
Long-term Quality of Life in Patients with Mycosis fungoides and Sezary Syndrome after low-dose Total Skin Electron Irradiation : Prospective StudyIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 57 - S58
-
Metastatic pigmented epithelioid melanocytoma in a 7-year-old femaleIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. 8, S. 1217 - 1219Online Volltext: dx.doi.org/ (Open Access)
-
Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphologyIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 340 - 347Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsIn: European Journal of Cancer (EJC) Jg. 159 (2021) S. 113 - 124Online Volltext: dx.doi.org/ (Open Access)
-
Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionIn: European Journal of Cancer (EJC) Jg. 148 (2021) S. 61 - 75Online Volltext: dx.doi.org/
-
Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries : A multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)In: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 6, S. 1763 - 1771Online Volltext: dx.doi.org/ (Open Access)
-
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibIn: Clinical Cancer Research Jg. 27 (2021) Nr. 16, S. 4500 - 4510Online Volltext: dx.doi.org/ (Open Access)
-
Surveillance of patients with conjunctival melanoma in German-speaking countries : A multinational survey of the German dermatologic cooperative oncology groupIn: European Journal of Cancer (EJC) Jg. 143 (2021) S. 43 - 45Online Volltext: dx.doi.org/
-
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseIn: European Journal of Cancer (EJC) Jg. 149 (2021) S. 37 - 48Online Volltext: dx.doi.org/ (Open Access)
-
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsIn: European Journal of Cancer (EJC) Jg. 155 (2021) S. 268 - 280Online Volltext: dx.doi.org/
-
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : A randomised, double-blind, placebo-controlled, phase 2 trialIn: Lancet Jg. 395 (2020) Nr. 10236, S. 1558 - 1568Online Volltext: dx.doi.org/
-
Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 26 (2020) Nr. 7, S. 1147Online Volltext: dx.doi.org/ (Open Access)
-
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy : Increased rate and mimicker of metastasisIn: European Journal of Cancer (EJC) Jg. 131 (2020) S. 18 - 26Online Volltext: dx.doi.org/
-
Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade : A Case ReportIn: Frontiers in Oncology Jg. 10 (2020) S. 592609Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
ECG Changes in Melanoma Patients Undergoing Cancer Therapy : Data from the ECoR RegistryIn: Journal of Clinical Medicine (JCM) Jg. 9 (2020) Nr. 7, 2060Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Jg. 31 (2020) Nr. 1, S. 144 - 152Online Volltext: dx.doi.org/ (Open Access)
-
Fatal swelling of the groin – Clear cell sarcoma : A rare but important differential diagnosis to malignant melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. 10, S. 1165 - 1168Online Volltext: dx.doi.org/ (Open Access)
-
GNAQ and GNA11 mutant nonuveal melanoma : A subtype distinct from both cutaneous and uveal melanomaIn: British Journal of Dermatology: BJD Jg. 183 (2020) Nr. 5, S. 928 - 939Online Volltext: dx.doi.org/ (Open Access)
-
Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy : A retrospective multicenter DeCOG study of 84 patientsIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 2, S. e000897Online Volltext: dx.doi.org/ (Open Access)
-
Immuntherapie beim malignen MelanomIn: Der Internist Jg. 61 (2020) Nr. 7, S. 669 - 675Online Volltext: dx.doi.org/ (Open Access)
-
Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma : A multicenter retrospective cohort study of the DeCOGIn: Journal for ImmunoTherapy of Cancer Jg. 8 (2020) Nr. 1, S. e000395Online Volltext: dx.doi.org/ (Open Access)
-
Malignes Melanom : Stellenwert der BRAF-Inhibition beim malignen MelanomIn: Der Onkologe Jg. 26 (2020) Nr. 8, S. 713 - 720Online Volltext: dx.doi.org/
-
Survival of patients with advanced metastatic melanoma : The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019In: European Journal of Cancer (EJC) Jg. 130 (2020) S. 126 - 138Online Volltext: dx.doi.org/
-
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma : A multi-institutional retrospective studyIn: The Journal of Dermatology Jg. 47 (2020) Nr. 6, S. 629 - 635Online Volltext: dx.doi.org/
-
Clinical and genetic analysis of melanomas arising in acral sitesIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 66 - 76Online Volltext: dx.doi.org/ (Open Access)
-
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases : a real-life multicenter studyIn: Melanoma Research Jg. 29 (2019) Nr. 1, S. 65 - 69Online Volltext: dx.doi.org/; Online Volltext: dx.doi.org/ (Open Access)
-
Evaluation of cutaneous adverse events of encorafenib and binimetinb : COMMENT on article by Graf et al.In: Journal of the European Academy of Dermatology and Venereology Jg. 33 (2019) Nr. 4, S. 630 - 631Online Volltext: dx.doi.org/ (Open Access)
-
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisIn: Cancer Immunology, Immunotherapy Jg. 68 (2019) Nr. 5, S. 765 - 772Online Volltext: dx.doi.org/
-
High PD-1 or PD-L1 Concentrations in the Serum of Melanoma Patients are predictive for reduced Therapeutic Success of PD-1 InhibitionIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 17 (2019) Nr. Suppl. 5, S. 7 - 7
-
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanomaIn: European Journal of Cancer (EJC) Jg. 119 (2019) S. 18 - 29Online Volltext: dx.doi.org/
-
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanomaIn: Nature Medicine Jg. 25 (2019) Nr. 12, S. 1916 - 1927Online Volltext: dx.doi.org/ (Open Access)
-
Metastatic Merkel cell carcinoma and myasthenia gravis : contraindication for therapy with immune checkpoint inhibitors?In: Journal for ImmunoTherapy of Cancer Jg. 7 (2019) Nr. 1, S. 141Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic factors for pulmonary metastasectomy in malignant melanoma : Size mattersIn: European Journal of Cardio-Thoracic Surgery Jg. 56 (2019) Nr. 6, S. 1104 - 1109Online Volltext: dx.doi.org/ (Open Access)
-
Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV⁶⁰⁰E inhibition in melanomaIn: European Journal of Cancer (EJC) Jg. 109 (2019) S. 137 - 153Online Volltext: dx.doi.org/
-
Treatment in metastatic melanoma : Time to re-thinkIn: Annals of Oncology Jg. 30 (2019) Nr. 4, S. 501 - 503Online Volltext: dx.doi.org/ (Open Access)
-
Advanced cutaneous squamous cell carcinoma : A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOGIn: European Journal of Cancer (EJC) Jg. 96 (2018) S. 34 - 43Online Volltext: dx.doi.org/
-
Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma : A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]In: European Journal of Cancer (EJC) Jg. 93 (2018) S. 158Online Volltext: dx.doi.org/ (Open Access)
-
Dose-dependent toxicity of ipilimumab in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 95 (2018) S. 104 - 108Online Volltext: dx.doi.org/
-
Fear of cancer progression in patients with stage IA malignant melanomaIn: European Journal of Cancer Care Jg. 27 (2018) Nr. 5, e12901Online Volltext: dx.doi.org/
-
Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockadeIn: European Journal of Cancer (EJC) Jg. 99 (2018) S. 58 - 65Online Volltext: dx.doi.org/
-
Predictors of quality of life in melanoma patients 4 years after diagnosis : Results of a nationwide cohort study in GermanyIn: Journal of Psychosocial Oncology Jg. 36 (2018) Nr. 6, S. 734 - 753Online Volltext: dx.doi.org/
-
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studyIn: European Journal of Cancer (EJC) Jg. 91 (2018) S. 116 - 124Online Volltext: dx.doi.org/ (Open Access)
-
Sebaceous tumours: more than skin deepIn: Gut Jg. 67 (2018) Nr. 11, S. 2045 - 2053Online Volltext: dx.doi.org/
-
The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy : A survey in German melanoma patients and their treating physiciansIn: OncoTarget Jg. 9 (2018) Nr. 40, S. 26217 - 26225Online Volltext: dx.doi.org/ (Open Access)
-
The safety and efficacy of dabrafenib and trametinib for the treatment of melanomaIn: Expert Opinion on Drug Safety Jg. 17 (2018) Nr. 1, S. 73 - 87Online Volltext: dx.doi.org/
-
Willingness to pay for a cure of low-risk melanoma patients in GermanyIn: PLoS ONE Jg. 13 (2018) Nr. 5, S. e0197780Online Volltext: dx.doi.org/ (Open Access)
-
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitisIn: European Journal of Cancer (EJC) Jg. 86 (2017) S. 248 - 256Online Volltext: dx.doi.org/
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris MelanomaIn: Investigative Ophthalmology & Visual Science, IOVS Jg. 58 (2017) Nr. 9, S. 3464 - 3470Online Volltext: dx.doi.org/ (Open Access)
-
Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanomaIn: European Journal of Cancer (EJC) Jg. 83 (2017) S. 142 - 145Online Volltext: dx.doi.org/
-
Immunotherapy in melanoma : Recent advances and future directionsIn: European Journal of Surgical Oncology Jg. 43 (2017) Nr. 3, S. 604 - 611Online Volltext: dx.doi.org/
-
Melanoma diagnosed in lesions previously treated by laser therapyIn: The Journal of Dermatology Jg. 44 (2017) Nr. 1, S. 23 - 28Online Volltext: dx.doi.org/
-
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunityIn: European Journal of Cancer (EJC) Jg. 75 (2017) S. 24 - 32Online Volltext: dx.doi.org/
-
SF3B1 and BAP1 mutations in blue nevus-like melanomaIn: Modern Pathology Jg. 30 (2017) Nr. 7, S. 928 - 939Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutationsIn: OncoTarget Jg. 8 (2017) Nr. 25, S. 40683 - 40692Online Volltext: dx.doi.org/ (Open Access)
-
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipientIn: European Journal of Cancer (EJC) Jg. 67 (2016) S. 66 - 72Online Volltext: dx.doi.org/
-
Making decisions on resectability and injectability status of lesions in the management of advanced melanoma in Germany, France and the UKIn: European Journal of Dermatology (EJD) Jg. 26 (2016) Nr. 5, S. 477 - 486Online Volltext: dx.doi.org/
-
Medikamentöse Therapie des metastasierten malignen MelanomsIn: Arzneimitteltherapie (AMT) Jg. 34 (2016) Nr. 1-2, S. 14 - 22
-
Oncogene status as a diagnostic tool in ocular and cutaneous melanomaIn: European Journal of Cancer (EJC) Jg. 57 (2016) S. 112 - 117Online Volltext: dx.doi.org/
-
Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapyIn: Medicine Jg. 95 (2016) Nr. 46, S. e5375Online Volltext: dx.doi.org/ (Open Access)
-
Actual practice of melanoma follow-up and treatment in Germany : results of a prospective, longitudinal cohort studyIn: British Journal of Dermatology: BJD Jg. 172 (2015) Nr. 6, S. 1646 - 1650Online Volltext: dx.doi.org/
-
Analysis of SDHD promoter mutations in various types of melanomaIn: OncoTarget Jg. 6 (2015) Nr. 28, S. 25868 - 25882Online Volltext: dx.doi.org/ (Open Access)
-
Analysis of SDHD promoter mutations in various types of melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 13 (2015) Nr. Suppl. 2, S. 11Online Volltext: dx.doi.org/
-
Combining BRAF(V) (600E) inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanomaIn: Experimental Dermatology Jg. 24 (2015) Nr. 9, S. 709 - 710Online Volltext: dx.doi.org/
-
Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of InfectionIn: PLoS ONE Jg. 10 (2015) Nr. 4, S. e0124590Online Volltext: dx.doi.org/ (Open Access)
-
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal MelanomaIn: PLoS ONE Jg. 10 (2015) Nr. 3, S. e0118564Online Volltext: dx.doi.org/ (Open Access)
-
Prospective evaluation of follow-up in melanoma patients in Germany : results of a multicentre and longitudinal studyIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. 5, S. 653 - 667Online Volltext: dx.doi.org/
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.In: Annals of Oncology Jg. 26 (2015) Nr. 1, S. 250 - 251Online Volltext: dx.doi.org/
-
Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly womanIn: British Journal of Dermatology: BJD Jg. 172 (2015) Nr. 6, S. 1642 - 1645Online Volltext: dx.doi.org/
-
The GERMELATOX DeCOG-trial : The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspectiveIn: European Journal of Cancer (EJC) Jg. 51 (2015) Nr. Suppl. 3, S. S671 - S672Online Volltext: dx.doi.org/
-
Therapie des malignen MelanomsIn: Der Onkologe Jg. 21 (2015) Nr. 10, S. 965 - 974Online Volltext: dx.doi.org/
-
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanomaIn: Annals of Oncology Jg. 25 (2014) Nr. 3, S. 747 - 753Online Volltext: dx.doi.org/
-
Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rashIn: Journal of the European Academy of Dermatology and Venereology Jg. 28 (2014) Nr. 12, S. 1685 - 1689Online Volltext: dx.doi.org/
-
Statin use and its effect on all-cause mortality of melanoma patients : a population-based Dutch cohort studyIn: Cancer Medicine Jg. 3 (2014) Nr. 5, S. 1284 - 1293Online Volltext: dx.doi.org/ (Open Access)
-
TERT promoter mutation status as an independent prognostic factor in cutaneous melanomaIn: Journal of the National Cancer Institute (JNCI) Jg. 106 (2014) Nr. 9,Online Volltext: dx.doi.org/
-
Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicityIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 30, S. 3844 - 3845Online Volltext: dx.doi.org/
-
Conjunctival Melanomas Harbor BRAF and NRAS Mutations—ResponseIn: Clinical Cancer Research Jg. 19 (2013) Nr. 22, S. 6331 - 6332Online Volltext: dx.doi.org/
-
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomasIn: Clinical Cancer Research Jg. 19 (2013) Nr. 12, S. 3143 - 3152Online Volltext: dx.doi.org/
-
Hautkrebsforschung reloaded : Paradigmenwechsel in der DermatoonkologieIn: Unikate: Berichte aus Forschung und Lehre (2013) Nr. 44: Medizin: 50 Jahre Universitätsklinikum Essen, S. 136 - 143Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Intracerebral metastases of malignant melanoma and their recurrences : a clinical analysisIn: Clinical Neurology and Neurosurgery Jg. 115 (2013) Nr. 9, S. 1721 - 1728Online Volltext: dx.doi.org/
-
Kombination von BRAF-Inhibitoren (BRAFi) und zerebraler Bestrahlung bei Patienten mit metastasiertem Melanom : Eine mögliche Behandlungsoption für neu aufgetretene oder pro-grediente Hirnmetastasen unter Therapie mit BRAF-InhibitorenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 11 (2013) Nr. 9, S. 952 - 952
-
β-Blocker use and all-cause mortality of melanoma patients : results from a population-based Dutch cohort studyIn: European Journal of Cancer (EJC) Jg. 49 (2013) Nr. 18, S. 3863 - 3871Online Volltext: dx.doi.org/
-
Advances and perspectives in immunotherapy of melanomaIn: Annals of Oncology Jg. 23 (2012) Nr. Suppl. 10, S. x104 - x108Online Volltext: dx.doi.org/ Online Volltext
-
Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF InhibitionIn: Journal of Clinical Oncology (JCO) Jg. 30 (2012) Nr. 19, S. 2375 - 2383Online Volltext: dx.doi.org/
-
Current advances and perspectives in the treatment of advanced melanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 5, S. 319 - 325Online Volltext: dx.doi.org/
-
Nebenwirkungsmanagement von AfatinibIn: TumorDiagnostik & Therapie Jg. 33 (2012) Nr. 3, S. 154 - 161Online Volltext: dx.doi.org/
-
Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its ManagementIn: Archives of Dermatology Jg. 148 (2012) Nr. 3, S. 357 - 361Online Volltext: dx.doi.org/
-
Side effects of systemic oncological therapies in dermatologyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 10 (2012) Nr. 7, S. 475 - 486Online Volltext: dx.doi.org/
-
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-upIn: European Journal of Cancer (EJC) Jg. 47 (2011) Nr. 13, S. 1977 - 1989Online Volltext: dx.doi.org/
-
EGFR-Inhibitoren und Multityrosinkinaseinhibitoren : Interdisziplinäre Behandlung der kutanen NebenwirkungenIn: Deutsche Medizinische Wochenschrift - DMW Jg. 136 (2011) Nr. 1-2, S. 39 - 44Online Volltext: dx.doi.org/
-
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma : A multicenter phase II DeCOG trialIn: Annals of Oncology Jg. 22 (2011) Nr. 7, S. 1667 - 1674Online Volltext: dx.doi.org/
-
Malignant melanoma and Wiedemann-Beckwith syndrome in childhoodIn: Klinische Pädiatrie Jg. 222 (2010) Nr. 6, S. 388 - 390Online Volltext: dx.doi.org/
-
PLX4032 : does it keep its promise for metastatic melanoma treatment?In: Expert Opinion on Investigational Drugs Jg. 19 (2010) Nr. 11, S. 1439 - 1449Online Volltext: dx.doi.org/
-
Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma : Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their ManagementIn: Seminars in Oncology Jg. 37 (2010) Nr. 5, S. 485 - 498Online Volltext: dx.doi.org/
-
Fertilitätserhalt beim Melanom : eine große Entlastung der BetroffenenIn: Die Dermatologie Jg. 74 (2023) Nr. 7, S. 479 - 480Online Volltext: dx.doi.org/ (Open Access)
-
Advanced stage melanoma during pregnancy : Real-world managementIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, 9540Online Volltext: dx.doi.org/
-
A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma : First results from the AliCe study
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S654 - S655Online Volltext: dx.doi.org/ -
Außergewöhnlicher Therapiebenefit von Imatinib bei cKIT-mutiertem Schleimhautmelanom mit nachfolgendem KIT-Mutationsverlust
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21 - 22Online Volltext: dx.doi.org/ (Open Access) -
Die PD-L1-Expression im Tumor prognostiziert je nach Art des untersuchten Gewebes das Outcome einer Anti-PD-1-basierten Immuntherapie bei metastasiertem Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 27 - 28Online Volltext: dx.doi.org/ (Open Access) -
Molekulare und klinische Charakterisierung von BRAF/NRAS/NF1-wt Melanomen
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 21Online Volltext: dx.doi.org/ (Open Access) -
Treatment decision for melanoma patients : Identification of similar patients at point of care
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 5 - 6Online Volltext: dx.doi.org/ (Open Access) -
Ultra-hypofraktionierte Ganzhautelektronenbestrahlung mit 2×4 Gy beim kutanen T-Zell-LymphomIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 199 (2023) Nr. Suppl. 1, S. S138 - S139Online Volltext: dx.doi.org/ (Open Access)
-
Untersuchung des klinischen Verlaufs von Melanompatienten mit einer Super-Response (CR/PR innerhalb von 3 Monaten) unter PD-1-basierter Immuncheckpoint-Inhibition : eine Subgruppen-Analyse der prospektiven multizentrischen Studie ADOREG
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 8 - 9Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC) : Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S903Online Volltext: dx.doi.org/ (Open Access) -
Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED) : Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S900Online Volltext: dx.doi.org/ (Open Access) -
Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients : a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 13 - 14Online Volltext: dx.doi.org/ -
Early safety signals from nivolumab in the adjuvant treatment of real-world melanoma patients derived from the German prospective non-interventional study NICO
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 18 - 19Online Volltext: dx.doi.org/ -
Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma : Interim analysis of the ImmunoCobiVem studyIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9548Online Volltext: dx.doi.org/
-
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 12 - 13Online Volltext: dx.doi.org/ -
Immune Checkpoint Inhibitor (ICI)-associated Pulmonary Manifestations (ICI-LM): Characterization of HRCT and BAL Findings
62. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V.; 25.–28.05.2022; Leipzig,In: Pneumologie Jg. 76 (2022) Nr. Supplement 1, S. S52Online Volltext: dx.doi.org/ -
Klinische und pathologische Merkmale des familiären Melanoms bei Keimbahn-TERT-Promotorvarianten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 6Online Volltext: dx.doi.org/ -
Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrenceIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 16_Suppl., S. 9570Online Volltext: dx.doi.org/ (Open Access)
-
Predictors of long-term survival of stage IV melanoma patients : a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 16 - 17Online Volltext: dx.doi.org/ -
Quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomasIn: European Journal of Cancer (EJC) Jg. 173 (2022) Nr. Suppl. 1, S. 20Online Volltext: dx.doi.org/
-
Therapiemanagement des ersten Rezidivs nach adjuvanter Therapie im Stadium III : multizentrische real-world Daten
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 3Online Volltext: dx.doi.org/ -
Additional Benefit of FDG-PET when Discontinuing Immune Checkpoint Inhibitor Therapy in Patients with metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 75 - 76
-
Bronchoalveolar lavage fluid (BALF) findings in patients with immune checkpoint inhibitor (ICI)-associated interstitial pneumonia (IP)In: European Respiratory Journal (ERJ) (2021) OA4240Online Volltext: dx.doi.org/
-
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl., S. 9578 - 9578Online Volltext: dx.doi.org/
-
Efficacy of low-dose Total Skin Electron Irradiation followed by oral Maintenance Retinoids in Patients with Mycosis Fungoides and Sezary SyndromeIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 172
-
Image-guided ablative Radiotherapy for Patients with multiple cerebral Metastases using Precision helical IrradiationIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics Jg. 197 (2021) Nr. Suppl. 1, S. 183
-
Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma : Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREGIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 59 - 60
-
PD-L1-Expression and Mutation Profile in pre-therapeutic Tumor Tissue as Predictors of the Therapeutic Success of PD-1-based Immune Checkpoint Inhibition Therapy in Patients with metastatic Melanoma : Evaluation of the prospective multicentric ADO-Study TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 19
-
PTHrP-induced hypercalcemia Psychosyndrome under Immune Checkpoint Blockade in Patients with penile Squamous Cell CarcinomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 23
-
Predictors of Super-response (CR/PR within 3 Months) under PD-1-based Immune Checkpoint Inhibition in metastatic Melanoma : A Subgroup Analysis of the prospective multicenter Study ADOREG TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 6 - 7
-
TERT Promoter Mutations associated with longer progression-free and Overall Survival under BRAF/MEK TherapyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 31
-
Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications : A retrospective, multicenter ADOReg StudyIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 15 - 16
-
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma : Final results from the dose-finding phase I part of the IMMU-Target trialIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 9532 - 9532Online Volltext: dx.doi.org/
-
Tumor PD-L1-Positivity in medical and digital Quantification predicts a favorable Patient Outcome for a PD-1-based Immune Checkpoint-Blockade in metastatic MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 19 (2021) Nr. Suppl. 4, S. 58 - 59
-
Agranulozytose unter Immuncheckpoint‐Blockade : Eine retrospektive, multizentrische AuswertungIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV28Online Volltext: dx.doi.org/ (Open Access)
-
Apoptotische Gastritis nach Immuncheckpointblockade : Ein typisches histopathologisches MusterIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. P12Online Volltext: dx.doi.org/ (Open Access)
-
Die Extracorporale Photopherese verbessert therapierefraktäre autoimmune Nebenwirkungen nach ImmuncheckpointblockadeIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV06Online Volltext: dx.doi.org/ (Open Access)
-
Die diagnostische Bedeutung der CT-gesteuerten Punktion bei HauttumorpatientenIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV49Online Volltext: dx.doi.org/ (Open Access)
-
Die digitale Analyse der Tumor PD‐L1 Expression ist ein guter Prädiktor des Therapieerfolgs einer anti‐PD1‐basierten Immuntherapie : Eine Subgruppenanalyse der multizentrischen translationalen Studie ADOREG/TRIMIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV36Online Volltext: dx.doi.org/ (Open Access)
-
Eindrucksvolles und schnelles Therapieansprechen eines metastasierten Adnexkarzinoms unter CemiplimabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV08Online Volltext: dx.doi.org/ (Open Access)
-
Neoadjuvante Immun‐ und zielgerichtete Therapie bei Melanompatienten im Stadium III BIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV44Online Volltext: dx.doi.org/ (Open Access)
-
Therapieentscheidung bei Indikation zur adjuvanten Therapie des Melanoms : Multizentrische Real World DataIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 18 (2020) Nr. Suppl. 2: Special Issue: Abstractband anlässlich des 30. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 09.–12. September 2020, S. FV43Online Volltext: dx.doi.org/ (Open Access)
-
Angiosarkom im Bereich des Capillitium mit der Symptomatik eines Quincke‐Ödems
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 34Online Volltext: dx.doi.org/ (Open Access) -
Auswirkungen der überarbeiteten AJCC‐Klassifikation (8. Edition) auf das Essener Melanomkollektiv
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 61 - 62Online Volltext: dx.doi.org/ (Open Access) -
Autoimmunbedingte Gastritis nach Immuncheckpoint‐Blockade : eine Fallserie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 26 - 27Online Volltext: dx.doi.org/ (Open Access) -
CCR5 Δ32 Polymorphismus als prädiktiver Marker für die Therapie mit Immuncheckpoint‐Inhibitoren beim Melanom
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 49 - 50Online Volltext: dx.doi.org/ (Open Access) -
Clear Cell Sarcoma - a rare Differential Diagnosis of malignant MelanomaIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. Suppl. 6, S. 3
-
Die Anzahl mutierter Melanom‐assoziierter Gene und die Expression von PD‐L1 sind unabhängige Prädiktoren der anti‐PD1 Immuntherapie ‐ eine prospektive Registerstudie der ADO (ADOREG/TRIM)In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 7 - 8Online Volltext: dx.doi.org/ (Open Access)
-
Einfluss einer vorangegangenen Radiatio auf den Erfolg einer immunonkologischen Therapie beim metastasierten Melanom – eine retrospektive multizentrische Studie der ADO
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28 - 29Online Volltext: dx.doi.org/ (Open Access) -
Klarzellsarkom – eine seltene Differentialdiagnose des malignen Melanoms
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 3Online Volltext: dx.doi.org/ (Open Access) -
Meningeosis melanomatosa : Schlechte Prognose trotz neuer Systemtherapeutika
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
Partielle Remission eines fortgeschrittenen Melanoms durch eine Kombinationstherapie mit Nivolumab und Trametinib nach Therapieversagen unter Ipilimumab + Nivolumab
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 38Online Volltext: dx.doi.org/ (Open Access) -
Therapieversagen der Immuncheckpoint‐Blockade mit PD1‐Antikörpern bei Patienten mit metastasierten Hauttumorerkrankungen und gleichzeitiger Immunsuppression durch eine Chronisch Lymphatische Leukämie
28. Deutschen Hautkrebskongresses (ADO‐Jahrestagung); 13.–15. September 2018; Stuttgart,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 16 (2018) Nr. S6, S. 28Online Volltext: dx.doi.org/ (Open Access) -
Diagnostik und Therapie der immunvermittelten Thyreoiditis unter Therapie mit Ipilimumab und NivolumabIn: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 15 (2017) Nr. Suppl. 3, S. 26 - 27Online Volltext: dx.doi.org/
-
The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatmentIn: Journal of Clinical Oncology (JCO) Jg. 32 (2014) Nr. 15, suppl., S. TPS9113Online Volltext: dx.doi.org/
-
Guideline-Based Context-Sensitive Decision Modeling for Melanoma PatientsIn: German Medical Data Sciences 2022 – Future Medicine: More Precise, More Integrative, More Sustainable! / Joint Conference of the 67th Annual Meeting of the German Association of Medical Informatics, Biometry, and Epidemiology e.V. (gmds) and the 14th Annual Meeting of the TMF – Technology, Methods, and Infrastructure for Networked Medical Research e.V.; 21–25 August 2022; Kiel, Germany / Röhrig, Rainer; Grabe, Niels; Hoffmann, Verena S.; Hübner, Ursula; König, Jochem; Sax, Ulrich; Schreiweis, Björn; Sedlmayr, Martin (Hrsg.) 2022, S. 50 - 57Online Volltext: dx.doi.org/ (Open Access)
-
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 44Online Volltext: dx.doi.org/ (Open Access) -
Ausgedehntes Rezidiv eines atypischen Fibroxanthoms
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO-Jahrestagung) 06.–09. September 2023 Hamburg, S. 99Online Volltext: dx.doi.org/ (Open Access) -
Einfluss der Hygieneregeln im Rahmen der Covid-19-Pandemie auf das psychosoziale Empfinden stationärer Hauttumor-Patienten
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 52 - 53Online Volltext: dx.doi.org/ (Open Access) -
Identifizierung von nachteiligen Datensamples zur verbesserten KI-gestützten Klassifizierung von Hautläsionen unter Verwendung von Radiomics
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 95 - 96Online Volltext: dx.doi.org/ (Open Access) -
Langfristiger Therapieerfolg von sequentieller Immun- und zielgerichteter Therapie beim metastasierten malignen Melanom
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 47 - 48Online Volltext: dx.doi.org/ (Open Access) -
Melanom mit unbekanntem Primarius (MUP) - eine monozentrische Auswertung
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 76 - 77Online Volltext: dx.doi.org/ (Open Access) -
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
ESMO Congress 2023 ; 20 - 24 October 2023 Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S694Online Volltext: dx.doi.org/ (Open Access) -
Pain points in software interaction in the treatment of melanoma patients
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 125 - 126Online Volltext: dx.doi.org/ (Open Access) -
Preliminary Examination of Cited Literature in International Melanoma Guidelines
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 126Online Volltext: dx.doi.org/ (Open Access) -
Therapieansprechen auf Sunitinib bei Imatinib-resistentem Rezidiv eines Dermatofibrosarkoma protuberans am Capillitium
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 99 - 100Online Volltext: dx.doi.org/ (Open Access) -
Therapieoption beim lokal fortgeschrittenen kutanen Plattenepithelkarzinom nach Cemiplimab-Resistenz
33. Deutscher Hautkrebskongress (ADO-Jahrestagung) ; 06.–09. September 2023, Hamburg, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 21 (2023) Nr. S4, Special Issue: Abstractband anlässlich des 33. Deutschen Hautkrebskongresses (ADO‐Jahrestagung) 06.–09. September 2023 Hamburg, S. 72Online Volltext: dx.doi.org/ (Open Access) -
Context-Sensitive Modeling of a Standard Operating Procedure for Melanoma Patient Treatment
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 67Online Volltext: dx.doi.org/ -
Explainable Radiomics by the example of malignant melanoma
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 65 - 66Online Volltext: dx.doi.org/ -
Genetic and methylation analysis of CTNNB1 mutations in benign and malignant melanocytic lesions
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 84Online Volltext: dx.doi.org/ -
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 29 - 30Online Volltext: dx.doi.org/ -
Konzept-basierte Erklärung neuronaler Netze für die Dermatohistopathologie
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 68Online Volltext: dx.doi.org/ -
Mitigating Cognitive Bias with Decision Support Systems
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 64Online Volltext: dx.doi.org/ -
Molekularpathologie und Methylierungsprofile als diagnostische Unterstützung zur Differenzierung von Klarzellsarkomen und melanozytären Tumoren
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 88Online Volltext: dx.doi.org/ -
Partielle Remission auf Cemiplimab eines beidseitig Orbitae-infiltrierenden Basalzellkarzinoms des Mittelgesichts
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 44 - 45Online Volltext: dx.doi.org/ -
Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
48th Annual Scientific Meeting Cancer care and research: Learning from the past and improving the future, 16-18 November 2021,In: Asia-Pacific Journal of Clinical Oncology Jg. 17 (2021) Nr. 9, SI, S. 162 - 163Online Volltext: dx.doi.org/ (Open Access)